Boehringer and Microsoft Partner on AI Digital Patient Twins

Boehringer Ingelheim and Microsoft announced a strategic collaboration to investigate Digital Patient Twins, computational models that use clinical and patient data to predict disease progression and forecast outcomes across different treatment scenarios. The two companies will assess feasibility across multiple disease areas, beginning with lung health research, and the scope explicitly includes advanced trial simulation and synthetic or hybrid control arms built from existing data.

"Exploring AI-enabled approaches, including the future potential of Digital Patient Twins, could support more patient-centric, informed and efficient clinical research," said Dr. Lykke Hinsch Gylvin, Chief Medical Officer at Boehringer Ingelheim. The announcement adds that "scientific quality, patient safety and regulatory requirements must always be upheld," wording that matters because any trial-usable application of these models eventually needs sign-off from regulators the release does not name.

Boehringer separately described its existing Microsoft Copilot rollout as "one of the largest Microsoft Copilot deployments in the pharmaceutical industry," with role-based applications, skills training and governance layered over broad employee access. The release discloses no cohort sizes, no indication-level targets within lung health, and no timeline for a first simulated or hybrid arm. The deal lands in the middle of a steady run of Microsoft healthcare AI moves we've been tracking, including last week's MAI-DxO diagnostic benchmark.